Parkinson’s Disease | Disease Landscape & Forecast | G7 | 2024
In the dynamic Parkinson’s disease (PD) market, recent advancements have been matched by notable challenges. Although the introduction of new brands, including Acorda’s Inbrija and AbbVie’s Vyalev / Produodopa, has broadened the spectrum of available treatments, the market has faced setbacks. For instance, Sunovion withdrew Kynmobi from the U.S. market and Ongentys experienced a temporary discontinuation. Further, therapies like Supernus’ SPN-830 have encountered regulatory hurdles delaying their launch. As developers seek to establish a niche for their products, the treatment algorithm will become more complex. While new brands can drive market value, intense competition and patient and payer cost sensitivity in a predominantly generic drug market make for a challenging launch environment. With generic alternatives available in all PD drug classes, new brands that lack clinical differentiation will have difficulty competing. A thorough grasp of current and future PD market dynamics is crucial for both new and established players vying for a share of this increasingly competitive landscape.
Questions answered:
- What will be the clinical and commercial impact of emerging levodopa reformulations (i.e., Vyalev / Produodopa, ND0612, and Crexont)?
- How do neurologists view the clinical prospects for emerging adjunctive therapies for motor fluctuations, dyskinesia, and dementia?
- Which putative disease-modifying therapies are most promising?
- How will neurologists adopt the new acute rescue therapies for “off” periods, and which unmet needs remain for other novel therapies targeting motor symptoms in PD?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 14 country-specific interviews with thought-leading neurologists; supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed and drug-treated prevalent cases of PD by country.
Emerging therapies: Preregistration: 1 drug; Phase 3: 3 drugs; Phase 2: 7 drugs
Market forecast features: 10-year, annualized, drug-level sales and patient shares of key PD therapies through 2033, segmented by brands / generics.
Key companies: AbbVie, Acadia Pharmaceuticals, Amneal Pharmaceuticals, Cerevel Therapeutics, Eisai, Hisamitsu Pharmaceutical, Kyowa Kirin, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, NeuroDerm, Pharma Two B, Sumitomo Dainippon Pharma, Sunovion, Supernus, Takeda, Teva, UCB, Zambon Pharma.
Key drugs: levodopa, amantadine, apomorphine, Crexont, Duodopa / Duopa, entacapone, Gocovri, Haruropi Tape, Inbrija, Kynmobi, Lecigon, ND0612, Neupro, Nourianz, Nuplazid, Ongentys, pramipexole, P2B001, rasagiline, ropinirole, Rytary, selegiline, tavapadon, Trerief, Vyalev / Produodopa, Xadago.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content d
